Medtronic plc (MDT)
NYSE · Healthcare · Medical Devices
$87.97+1.84%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $113B
- P/E (trailing)
- 21.6
- Forward P/E
- 13.7
- Dividend yield
- 3.3%
- 52-week range
- $73.31 – $106.33
- 52-week change
- −12.24%
- EPS (trailing)
- $4.07
- Analyst rating
- 1.8 Buy
- Next earnings
- Nov 17, 2026
Fiscal year to Apr 2026
- Revenue
- $36.4B (+8.43%)
- Net income
- $5K
- Operating margin
- 17.8%
- Diluted EPS
- $3.73
- Free cash flow
- $5.4B
From the company’s annual report on SEC EDGAR.
About Medtronic plc
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products.
Headquarters: Galway, Ireland · 95,000 employees · medtronic.com